Ivonescimab Fails to Secure FDA Approval Following Nonsignificant Overall Survival Benefit in HARMONi
Clinical Summary:
- Regulatory Update: The US Food and Drug Administration has issued a Complete Response Letter for the biologics license application seeking approval of ivonescimab plus platinum-containing chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer previously treated with an EGFR tyrosine kinase inhibitor.
- Key Outcomes: The phase 3 HARMONi trial met its progression-free survival (PFS) primary end point but did not demonstrate a statistically significant overall survival (OS) improvement. The FDA determined that the PFS benefit without a significant OS benefit did not establish a favorable benefit-risk profile to support approval.
- Clinical Relevance: The decision highlights the importance of demonstrating clinically meaningful survival benefits when evaluating new treatment combinations. Ivonescimab remains investigational in the US, with additional clinical development ongoing across multiple tumor types.
The US Food and Drug Administration (FDA) has issued a Complete Response Letter for the biologics license application seeking approval of ivonescimab plus platinum-containing chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with an EGFR tyrosine kinase inhibitor (TKI).
The November 15, 2026, announcement from Summit Therapeutics confirmed that the FDA determined the application could not be approved in its current form because the phase 3 HARMONi trial failed to demonstrate a significant overall survival (OS) benefit, leaving substantial evidence of effectiveness insufficient to support approval.
The FDA concluded that the progression-free survival (PFS) benefit observed with ivonescimab plus chemotherapy, in the absence of a statistically significant OS benefit, did not support a favorable benefit-risk profile for approval.
This double-blind trial evaluated ivonescimab, an investigational PD-1/VEGF bispecific antibody, in combination with platinum-containing chemotherapy compared with placebo plus platinum-containing chemotherapy in patients with EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC who were previously treated with a third-generation EGFR TKI. Primary end points included PFS and OS.
The study met its primary PFS end point, demonstrating a statistically significant improvement with ivonescimab plus chemotherapy compared with chemotherapy alone. However, the primary OS analysis demonstrated a numerical trend favoring ivonescimab without reaching statistical significance.
In a post hoc analysis incorporating longer-term follow-up of Western patients, the hazard ratio (HR) for OS was 0.76 in the overall population, Asian patients, and Western patients, according to Summit Therapeutics.
Although the post hoc findings suggested a consistent numerical OS benefit across geographic regions, they did not establish a statistically significant survival improvement sufficient to support FDA approval.
Detailed efficacy results, including median PFS, median OS, and statistical comparisons from the primary analyses, were not provided in the announcement.
The safety profile of ivonescimab plus chemotherapy was reported to be acceptable and manageable, with no new safety signals identified.
Treatment-related adverse events led to discontinuation of ivonescimab in 16 patients (7.3%) compared with discontinuation of placebo in 11 patients (5%) in the control arm. Treatment-related adverse events resulted in death in 4 patients (1.8%) receiving ivonescimab plus chemotherapy compared with 5 patients (2.3%) receiving chemotherapy alone.
This FDA decision represents a regulatory setback for ivonescimab in previously treated EGFR-muated advanced NSCLC, although the agent remains under investigation across multiple tumor types and treatment settings.
Ivonescimab remains investigational and is not FDA approved in the United States, although it previously received marketing authorization in China.
Summit Therapeutics stated that it remains committed to advancing ivonescimab development through its broader clinical program despite the FDA's decision regarding the HARMONi application.
Source:
Summit Therapeutics Inc. Summit Therapeutics provides update regarding ivonescimab biologics license application. Accessed on: November 16, 2026. https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/


